Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis
Michael A. Kamm(St Vincent's Hospital), Raymond E. Joseph(Takeda (United States)), Stefan Schreiber(Goethe University Frankfurt), Todd Butler(Takeda (United States)), David D. Stephenson(Basingstoke and North Hampshire Hospital), L Jackowski, Andrew Lyne(Basingstoke and North Hampshire Hospital), M A Gassull(Universitat Autònoma de Barcelona), Mary Palmen(Basingstoke and North Hampshire Hospital), William J. Sandborn(Mayo Clinic)
Cited by 352
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k